Company Active LTD

Company profile

Antiverse Ltd

Antiverse

Antiverse Ltd is a UK company with status active founded in 2017 based in Wales.

CRN
10736975
Founded
2017
Age
9

Overview

Legal name
ANTIVERSE LTD
Region
Wales
Registered address
SBARC, SPARK 5TH FLOOR
MAINDY RD
CARDIFF
UNITED KINGDOM
CF24 4HQ
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

9 events
31 Jan
2027

Accounts due

Accounts Due

Next accounts due date

13 Jun
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

09 Jun
2026

Resolution

Resolution

RESOLUTIONS | Transaction WUYzMTBBVEVhZGlxemtjeA | Paper/PDF filed

Published 09 Jun 2026 22:49

08 Jun
2026

Memorandum Articles

Incorporation

MA | Transaction MzUyNDEwMDcyNmFkaXF6a2N4 | Paper/PDF filed

Published 09 Jun 2026 22:48

07 Jun
2026

Appoint Person Director Company With Name Date

Officers

AP01 | Transaction MzUyNTU5MTc3OGFkaXF6a2N4

Published 07 Jun 2026 07:46

30 May
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Apr
2025

Accounts filed

Accounts

Last accounts made up date

19 Feb
2025

Capital Allotment Shares

Capital

SH01 | Transaction MzQ1NTY4MjY1NmFkaXF6a2N4

Published 19 Feb 2025 01:05

24 Apr
2017

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2018
Funded years
2018, 2020
Age at first award
1 years

Projects

2020 Collaborative R&D Lead participant

Antibody Discovery Platform with Machine Learning

1 Jul 2020 to 31 Mar 2023

Awarded
£554,575
Total cost £1,109,150

Antibodies are produced by the body's plasma cells and used by the immune system to combat pathogens that cause disease e.g. bacteria or viruses. An effective antibody should specifically target a component of the pathogen (known as an antigen) and bind to it, resulting in its neutralisation. Antibody discovery is an expensive and time-consuming process. ...

2018 Feasibility Studies Lead participant

Computational Antibody Design with Machine Learning

1 Oct 2018 to 31 Dec 2019

Awarded
£69,748
Total cost £99,633

"Due to their high specificity and low toxicity, antibodies are attractive candidates for improved, more efficient, easier to deliver, and safer therapeutics. In 2016, 5/10 best-selling drugs worldwide were antibodies, including the record-breaking Humira which took £12bn in sales, the highest ever for any pharmaceutical. The global antibody therapeutics ...

Product types

Collaborative R&D Feasibility Studies